The New Ice Age of Musculoskeletal Intervention: Role of Percutaneous Cryoablation in Bone and Soft Tissue Tumors.
Nicolas PapalexisLeonor Garbin SavareseGiuliano PetaConstantino ErraniGianmarco TuzzatoPaolo SpinnatoFederico PontiMarco MiceliGiancarlo FacchiniPublished in: Current oncology (Toronto, Ont.) (2023)
In the rapidly evolving field of interventional oncology, minimally invasive methods, including CT-guided cryoablation, play an increasingly important role in tumor treatment, notably in bone and soft tissue cancers. Cryoablation works using compressed gas-filled probes to freeze tumor cells to temperatures below -20 °C, exploiting the Joule-Thompson effect. This cooling causes cell destruction by forming intracellular ice crystals and disrupting blood flow through endothelial cell damage, leading to local ischemia and devascularization. Coupling this with CT technology enables precise tumor targeting, preserving healthy surrounding tissues and decreasing postoperative complications. This review reports the most important literature on CT-guided cryoablation's application in musculoskeletal oncology, including sarcoma, bone metastases, and bone and soft tissue benign primary tumors, reporting on the success rate, recurrence rate, complications, and technical aspects to maximize success for cryoablation in the musculoskeletal system.
Keyphrases
- soft tissue
- blood flow
- minimally invasive
- image quality
- dual energy
- computed tomography
- contrast enhanced
- room temperature
- palliative care
- randomized controlled trial
- positron emission tomography
- endothelial cells
- systematic review
- gene expression
- small molecule
- single cell
- magnetic resonance imaging
- bone mineral density
- adverse drug
- stem cells
- cancer therapy
- young adults
- drug delivery
- body composition
- single molecule
- pet ct
- combination therapy
- bone loss
- photodynamic therapy
- bone regeneration
- replacement therapy